Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: A phase I, open-label, dose-escalation clinical study-Reference-Cited by-同舟云学术

Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: A phase I, open-label, dose-escalation clinical study

Published:2008-10 Issue:10 Volume:30 Page:1806-1816
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Burge Daniel J.,Bookbinder Stephen A.,Kivitz Alan J.,Fleischmann Roy M.,Shu Cathye,Bannink Jeannette

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference41 articles.

1. Joint damage and disability in rheumatoid arthritis: An updated systematic review;Scott;Clin Exp Rheumatol,2003

2. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period;Doran;Arthritis Rheum,2002

3. Review of UK data on the rheumatic diseases-2. Rheumatoid arthritis;Hazes;Br J Rheumatol,1990

4. Factors predicting death, survival and functional outcome in a prospective study of early rheumatoid disease over fifteen years;Corbett;Br J Rheumatol,1993

5. Guidelines for the management of rheumatoid arthritis: 2002 Update;The American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines;Arthritis Rheum,2002

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The applications of anti-CD20 antibodies to treat various B cells disorders;Biomedicine & Pharmacotherapy;2019-01

2. Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus;Clinical Therapeutics;2016-06

3. Emerging therapies for refractory chronic lymphocytic leukemia;Leukemia & Lymphoma;2014-06-27

4. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics;Critical Reviews in Biotechnology;2013-10-24

5. Monoclonal antibody treatments for rheumatoid arthritis;Expert Opinion on Biological Therapy;2013-06-21